Physician profile
Samuel Pegram
NPI 1528043130
$20,228.46
in general payments reported to CMS, 2019-2025
42 companies · $3,530 in 2025
The $3,530 reported for 2025 was more than what 80% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,775 · 2020: $1,001 · 2021: $2,202 · 2022: $4,027 · 2023: $3,840 · 2024: $3,853 · 2025: $3,530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,123.83 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,065.40 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $2,539.48 | 2019-2025 | |
| Ucb, INC. | $1,842.37 | 2019-2025 | Bimzelx, Cimzia |
| Aurinia Pharma U.S., INC. | $1,528.54 | 2021-2025 | Lupkynis |
| Janssen Biotech, INC. | $1,383.53 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Pfizer INC. | $1,230.37 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,108.62 | 2021-2025 | Saphnelo |
| Horizon Therapeutics Plc | $1,072.71 | 2019-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,051.87 | 2019-2025 | Ofev, Cyltezo |
| Mallinckrodt Hospital Products INC. | $936.86 | 2021-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $862.30 | 2022-2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $852.95 | 2019-2025 | |
| Glaxosmithkline, LLC. | $549.15 | 2019-2025 | Benlysta, Nucala |
| Abbott Laboratories | $445.54 | 2023-2024 | Octrode, Proclaim |
| Radius Health, INC. | $258.54 | 2019-2023 | Tymlos |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $224.05 | 2019-2020 | |
| Lilly USA, LLC | $213.75 | 2022-2024 | Taltz |
| Mallinckrodt Enterprises LLC | $123.76 | 2019 | |
| Alexion Pharmaceuticals, INC. | $102.96 | 2022-2025 | Strensiq |
| E.R. Squibb & Sons, L.L.C. | $101.21 | 2019-2024 | Orencia |
| Antares Pharma, INC. | $89.80 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $74.60 | 2019-2021 | |
| Celgene Corporation | $72.00 | 2019 | |
| Genzyme Corporation | $71.71 | 2019-2020 | |
| Organon LLC | $70.88 | 2023-2025 | Hadlima, Renflexis |
| Actelion Pharmaceuticals US, INC. | $51.16 | 2023 | Opsumit |
| Redhill Biopharma INC. | $40.01 | 2021 | |
| Medexus Pharma, INC. | $38.63 | 2019 | |
| Astellas Pharma US INC | $38.23 | 2019 | |
| Alnylam Pharmaceuticals INC. | $29.62 | 2024 | Givlaari |
| Si-Bone, INC. | $24.13 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $23.45 | 2021 | |
| Alkermes, INC. | $21.10 | 2020 | |
| United Therapeutics Corporation | $19.52 | 2021 | |
| Upsher-Smith Laboratories LLC | $19.06 | 2021 | |
| Collegium Pharmaceutical, INC. | $13.72 | 2021 | |
| Forte Bio-Pharma LLC | $13.51 | 2021 | |
| Sandoz INC. | $12.70 | 2023 | |
| Grt US Holding, INC. | $10.67 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Pegram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.